Effect of Postoperative Prolonged sedation with Dexmedetomidine after successful reperfusion with Endovascular Thrombectomy on long-term prognosis in patients with acute ischemic stroke (PPDET): study protocol for a randomized controlled trial

Li-na Yang,Yi Sun,Yu-zhu Wang,Jing Wang,Yi-sha Qi,Shan-shan Mu,Yun-peng Liu,Zi-qing Zhang,Zi-mo Chen,Xiao-jie Wang,Wu-xiang Xie,Chang-wei Wei,Yang Wang,An-shi Wu

DOI: https://doi.org/10.1186/s13063-024-08015-x

IF: 2.728

2024-03-06

Trials

Abstract:Endovascular thrombectomy (EVT) is a standard treatment for acute ischemic stroke (AIS) with large vessel occlusion. Hypertension and increased blood pressure variability within the first 24 h after successful reperfusion are related to a higher risk of symptomatic intracerebral hemorrhage and higher mortality. AIS patients might suffer from ischemia-reperfusion injury following reperfusion, especially within 24 h. Dexmedetomidine (DEX), a sedative commonly used in EVT, can stabilize hemodynamics by inhibiting the sympathetic nervous system and alleviate ischemia-reperfusion injury through anti-inflammatory and antioxidative properties. Postoperative prolonged sedation for 24 h with DEX might be a potential pharmacological approach to improve long-term prognosis after EVT.

medicine, research & experimental

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate whether long - term sedation with dexmedetomidine (DEX) after surgery can improve the long - term prognosis of patients with acute ischemic stroke (AIS) after successful endovascular thrombectomy (EVT). Specifically, the main objective of the study is to verify whether long - term DEX sedation after surgery can promote the functional independence of patients (measured by a modified Rankin scale [mRS] score of 0 - 2 after 90 days). Secondary objectives include evaluating changes in stroke severity within 24 hours and 7 days after EVT, changes in the volume of the ischemic penumbra/infarct volume, the length of ICU/hospital stay, and all - cause mortality within 90 days.

The research background indicates that although EVT has become the standard method for treating AIS and has a high successful reperfusion rate, only about 40% - 55% of patients can achieve functionally independent results. In addition, an increase in hypertension and blood pressure variability within 24 hours after reperfusion is associated with an increased risk of symptomatic intracranial hemorrhage, which may lead to a higher mortality rate. Dexmedetomidine, as a selective α2 - adrenergic receptor agonist, has the effects of stabilizing hemodynamics, reducing the inflammatory response, and antioxidant stress, and may help to reduce reperfusion injury, thereby improving the long - term prognosis of patients.

Therefore, this randomized controlled trial aims to explore the effectiveness and safety of long - term DEX sedation after surgery on the long - term prognosis of AIS patients. By comparing two groups of patients who received DEX sedation and those who received an equal amount of normal saline sedation, the study is expected to provide important evidence regarding the potential value of DEX in improving the long - term prognosis of AIS patients.